Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1260825.RAXYO-Evk4g9CO1EposGC4SXTUlVfgfWwI-3Cb6z0LHxw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1260825.RAXYO-Evk4g9CO1EposGC4SXTUlVfgfWwI-3Cb6z0LHxw130_assertion type Assertion NP1260825.RAXYO-Evk4g9CO1EposGC4SXTUlVfgfWwI-3Cb6z0LHxw130_head.
- NP1260825.RAXYO-Evk4g9CO1EposGC4SXTUlVfgfWwI-3Cb6z0LHxw130_assertion description "[MIR-93 mRNA expression was also negatively associated with differentiation (well vs. poor and moderate) and International Federation of Gynecology and Obstetrics staging (FIGO stage I/II vs. stage III/IV) in ovarian carcinoma (p?<?0.05), besides, miR-93 was higher expressed in mucinous adenocarcinoma than the other types (p?<?0.05).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1260825.RAXYO-Evk4g9CO1EposGC4SXTUlVfgfWwI-3Cb6z0LHxw130_provenance.
- NP1260825.RAXYO-Evk4g9CO1EposGC4SXTUlVfgfWwI-3Cb6z0LHxw130_assertion evidence source_evidence_literature NP1260825.RAXYO-Evk4g9CO1EposGC4SXTUlVfgfWwI-3Cb6z0LHxw130_provenance.
- NP1260825.RAXYO-Evk4g9CO1EposGC4SXTUlVfgfWwI-3Cb6z0LHxw130_assertion SIO_000772 25649143 NP1260825.RAXYO-Evk4g9CO1EposGC4SXTUlVfgfWwI-3Cb6z0LHxw130_provenance.
- NP1260825.RAXYO-Evk4g9CO1EposGC4SXTUlVfgfWwI-3Cb6z0LHxw130_assertion wasDerivedFrom befree-2016 NP1260825.RAXYO-Evk4g9CO1EposGC4SXTUlVfgfWwI-3Cb6z0LHxw130_provenance.
- NP1260825.RAXYO-Evk4g9CO1EposGC4SXTUlVfgfWwI-3Cb6z0LHxw130_assertion wasGeneratedBy ECO_0000203 NP1260825.RAXYO-Evk4g9CO1EposGC4SXTUlVfgfWwI-3Cb6z0LHxw130_provenance.